Antiobesity pharmacotherapy: New drugs and emerging targets

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 53-66

  Kim, G W ^a   Lin, J E ^a   Blomain, E S ^a   Waldman, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; APPETITE STIMULANT; CETILISTAT; CYCLIC GMP; DAVALINTIDE; DESVENLAFAXINE; EXENDIN 4; FENFLURAMINE; LEPTIN; LIRAGLUTIDE; LORCASERIN; METRELEPTIN; OSYMIA; OXYNTOMODULIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; VELNEPERIT;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; EATING HABIT; ENERGY METABOLISM; EXCITABILITY; EXERCISE; FATIGUE; FEAR; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE COST; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; INFECTION; LIFESTYLE MODIFICATION; LIPID ABSORPTION; LIVER TOXICITY; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NERVOUSNESS; NONHUMAN; OBESITY; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIPELINE; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SINUSITIS; STEATORRHEA; SUDDEN CARDIAC DEATH; SUDDEN DEATH; SUICIDAL IDEATION; SUICIDE; TREMOR; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84890919810     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.204     Document Type: Article

References (104)

1. Malik, V.S., Willett, W.C. & Hu, F.B. Global obesity: trends, risk factors and policy implications. Nat. Rev. Endocrinol. 9, 13-27 (2013).
2. Wang, Y.C., McPherson, K., Marsh, T., Gortmaker, S.L. & Brown, M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378, 815-825 (2011).
3. Kopelman, P.G. Obesity as a medical problem. Nature 404, 635-643 (2000). (Pubitemid 30205068)
4. AMA Adopts New Policies on Second Day of Voting at Annual Meeting. (2013).
5. Kim, G.W., Lin, J.E., Blomain, E.S. & Waldman, S.A. New advances in models and strategies for developing anti-obesity drugs. Expert Opin. Drug Discov. 8, 655-671 (2013).
6. Obesity Society supports efforts to reduce consumption of sugar-sweetened beverages. (2012).
7. Robert Wood Johnson Foundation. New Report: Adult Obesity Rates Hold Steady But Remain High. (2013).
8. DeMaria, E.J. Bariatric surgery for morbid obesity. N. Engl. J. Med. 356, 2176-2183 (2007).
9. Zimmet, P. & Alberti, K.G. Surgery or medical therapy for obese patients with type 2 diabetes? N. Engl. J. Med. 366, 1635-1636 (2012).
10. Connolly, H.M. et al. Valvular heart disease associated with fenfluraminephentermine. N. Engl. J. Med. 337, 581-588 (1997). (Pubitemid 27360757)
11. Asher, W.L. Mortality rate in patients receiving "diet pills." Curr. Ther. Res. Clin. Exp. 14, 525-539 (1972).
12. Kernan, W.N. et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med. 343, 1826-1832 (2000). (Pubitemid 32104127)
13. Haller, C.A. & Benowitz, N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 343, 1833-1838 (2000). (Pubitemid 32104128)
14. US Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). (2010).
15. Topol, E.J. et al.; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebocontrolled trial. Lancet 376, 517-523 (2010).
16. European Medicines Agency. Withdrawal of the marketing authorisation application for Belviq (lorcaserin). (2013).
17. European Medicines Agency. Refusal of the marketing authorisation for Qsiva (phentermine/topiramate). (2013).
18. Davidson, M.H. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242 (1999). (Pubitemid 29058112)
19. Public Citizen. Petition to Ban Orlistat (Alli, Xenical). (2011).
20. Song, B.M. & Avery, L. Serotonin activates overall feeding by activating two separate neural pathways in Caenorhabditis elegans. J. Neurosci. 32, 1920-1931 (2012).
21. Fink, K.B. & Göthert, M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 59, 360-417 (2007).
22. Yeo, G.S. & Heisler, L.K. Unraveling the brain regulation of appetite: lessons from genetics. Nat. Neurosci. 15, 1343-1349 (2012).
23. Heisler, L.K. et al. Activation of central melanocortin pathways by fenfluramine. Science 297, 609-611 (2002). (Pubitemid 34815346)
24. Heisler, L.K. et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51, 239-249 (2006). (Pubitemid 44063615)
25. Fleming, J.W., McClendon, K.S. & Riche, D.M. New obesity agents: lorcaserin and phentermine/topiramate. Ann. Pharmacother. 47, 1007-1016 (2013).
26. Saudou, F. et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 265, 1875-1878 (1994).
27. Xu, Y. et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60, 582-589 (2008).
28. Wu, Q., Clark, M.S. & Palmiter, R.D. Deciphering a neuronal circuit that mediates appetite. Nature 483, 594-597 (2012).
29. Astrup, A. Drug management of obesity-efficacy versus safety. N. Engl. J. Med. 363, 288-290 (2010).
30. Halford, J.C., Boyland, E.J., Lawton, C.L., Blundell, J.E. & Harrold, J.A. Serotonergic anti-obesity agents: past experience and future prospects. Drugs 71, 2247-2255 (2011).
31. Smith, S.R. et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245-256 (2010).
32. O'Neil, P.M. et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20, 1426-1436 (2012).
33. Fidler, M.C. et al.; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067-3077 (2011).
34. Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F. & Fitchet, M.; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. Relat. Metab. Disord. 28, 1399-1410 (2004). (Pubitemid 39481843)
35. Astrup, A. et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 12, 1658-1669 (2004). (Pubitemid 41132475)
36. Bray, G.A. et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11, 722-733 (2003). (Pubitemid 41151598)
37. Topamax (Topiramate) [product information]. Titusville, NJ: Janssen Pharmaceuticals, 2012.
38. Richard, D., Ferland, J., Lalonde, J., Samson, P. & Deshaies, Y. Influence of topiramate in the regulation of energy balance. Nutrition 16, 961-966 (2000).
39. Richard, D., Picard, F., Lemieux, C., Lalonde, J., Samson, P. & Deshaies, Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. Relat. Metab. Disord. 26, 344-353 (2002). (Pubitemid 34226159)
40. Picard, F., Deshaies, Y., Lalonde, J., Samson, P. & Richard, D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 8, 656-663 (2000).
41. Allison, D.B. et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20, 330-342 (2012).
42. Gadde, K.M. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341-1352 (2011).
43. Garvey, W.T. et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 95, 297-308 (2012).
44. Vivus. Vivus Announces FDA Approval of Once Daily Qsymia (Phentermine and Topiramate Extended-release) Capsules CIV. .
45. Hendricks, E.J. et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int. J. Obes. (Lond). (2013); e-pub ahead of print 17 May 2013.
46. Khazaal, Y. & Zullino, D.F. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur. J. Clin. Pharmacol. 63, 891-2; author reply 893 (2007). (Pubitemid 47237895)
47. McElroy, S.L., Hudson, J.I., Capece, J.A., Beyers, K., Fisher, A.C. & Rosenthal, N.R.; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebocontrolled study. Biol. Psychiatry 61, 1039-1048 (2007). (Pubitemid 46551975)
48. Shin, J.H. & Gadde, K.M. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes. Metab. Syndr. Obes. 6, 131-139 (2013).
49. Krishna, R. et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin. Pharmacol. Ther. 86, 659-666 (2009).
50. Wikberg, J.E. & Mutulis, F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov. 7, 307-323 (2008).
51. Wessells, H., Gralnek, D., Dorr, R., Hruby, V.J., Hadley, M.E. & Levine, N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 56, 641-646 (2000).
52. Larhammar, D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 65, 165-174 (1996). (Pubitemid 26325603)
53. Omori, N. et al. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg. Med. Chem. Lett. 22, 2020-2023 (2012).
54. Erondu, N. et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4, 275-282 (2006). (Pubitemid 44430911)
55. Sargent, B.J. & Moore, N.A. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol. 68, 852-860 (2009).
56. Greenway, F.L. et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17, 30-39 (2009). (Pubitemid 50324544)
57. Pittner, R.A. et al. Molecular physiology of amylin. J. Cell. Biochem. 55 (suppl.), 19-28 (1994). (Pubitemid 24199282)
58. Koda, J.E., Fineman, M., Rink, T.J., Dailey, G.E., Muchmore, D.B. & Linarelli, L.G. Amylin concentrations and glucose control. Lancet 339, 1179-1180 (1992).
59. Edwards, G.L., Gedulin, B.R., Jodka, C., Dilts, R.P., Miller, C.C. & Young, A. Area postrema (AP)- lessions block the regulation of gastric emptying by amylin. Neuro. Gastroenterol. Motil. 10, 26 (1998).
60. Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T. & Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/ nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord. 25, 1005-1011 (2001). (Pubitemid 32566055)
61. Maggs, D., Shen, L., Strobel, S., Brown, D., Kolterman, O. & Weyer, C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metab. Clin. Exp. 52, 1638-1642 (2003). (Pubitemid 38049286)
62. Montague, C.T. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903-908 (1997). (Pubitemid 27289591)
63. Farooqi, I.S. & O'Rahilly, S. Monogenic obesity in humans. Annu. Rev. Med. 56, 443-458 (2005). (Pubitemid 40299792)
64. Ozcan, L. et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35-51 (2009).
65. Roth, J.D. et al. Leptin responsiveness restored by amylin agonism in dietinduced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257-7262 (2008). (Pubitemid 351754465)
66. Ravussin, E. et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 17, 1736-1743 (2009).
67. Amylin Pharmaceuticals. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial. (2011).
68. Müller, T.D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383-393 (2012).
69. Drucker, D.J. The biology of incretin hormones. Cell Metab. 3, 153-165 (2006).
70. Meeran, K. et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140, 244-250 (1999). (Pubitemid 29011165)
71. Turton, M.D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72 (1996). (Pubitemid 26008136)
72. Flint, A., Raben, A., Astrup, A. & Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515-520 (1998). (Pubitemid 28084232)
73. Näslund, E. et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 91, 439-446 (2004). (Pubitemid 38386908)
74. Michel, M.C., Fliers, E. & Van Noorden, C.J. Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch. Pharmacol. 377, 205-207 (2008).
75. Amori, R.E., Lau, J. & Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298, 194-206 (2007). (Pubitemid 47057766)
76. Fakhoury, W.K., Lereun, C. & Wright, D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86, 44-57 (2010).
77. Phung, O.J., Scholle, J.M., Talwar, M. & Coleman, C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303, 1410-1418 (2010).
78. Pratley, R.E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J. Med. 10, 171 (2008).
79. Batterham, R.L. et al. Inhibition of food intake in obese subjects by peptide YY 3-36. N. Engl. J. Med. 349, 941-948 (2003). (Pubitemid 37064767)
80. Sutherland, E.W. & Robison, G.A. The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes 18, 797-819 (1969).
81. Unger, R.H., Dobbs, R.E. & Orci, L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu. Rev. Physiol. 40, 307-343 (1978). (Pubitemid 8351311)
82. Marchmont, R.J. & Houslay, M.D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187, 381-392 (1980).
83. Zhao, A.Z., Zhao, H., Teague, J., Fujimoto, W. & Beavo, J.A. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc. Natl. Acad. Sci. USA 94, 3223-3228 (1997). (Pubitemid 27157292)
84. Hawley, S.A. et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9-19 (2005). (Pubitemid 43239821)
85. Hardie, D.G. & Frenguelli, B.G. A neural protection racket: AMPK and the GABA(B) receptor. Neuron 53, 159-162 (2007). (Pubitemid 46074408)
86. Narkar, V.A. et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405-415 (2008).
87. Minokoshi, Y. et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428, 569-574 (2004). (Pubitemid 38480541)
88. Lucas, K.A. et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414 (2000).
89. Degerman, E. et al. From PDE3B to the regulation of energy homeostasis. Curr. Opin. Pharmacol. 11, 676-682 (2011).
90. Nisoli, E. et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299, 896-899 (2003). (Pubitemid 36182449)
91. Jang, Y., Wang, H., Xi, J., Mueller, R.A., Norfleet, E.A. & Xu, Z. NO mobilizes intracellular Zn2+ via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes. Cardiovasc. Res. 75, 426-433 (2007). (Pubitemid 46961936)
92. Cypess, A.M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517 (2009).
93. Trujillo, M.E. & Scherer, P.E. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 27, 762-778 (2006). (Pubitemid 44936059)
94. Parker, N., Crichton, P.G., Vidal-Puig, A.J. & Brand, M.D. Uncoupling protein-1 (UCP1) contributes to the basal proton conductance of brown adipose tissue mitochondria. J. Bioenerg. Biomembr. 41, 335-342 (2009).
95. Kozak, L.P. & Koza, R.A. The genetics of brown adipose tissue. Prog. Mol. Biol. Transl. Sci. 94, 75-123 (2010).
96. Haas, B. et al. Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci. Signal. 2, ra78 (2009).
97. Mitschke, M.M. et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 27, 1621-1630 (2013).
98. Moro, C., Galitzky, J., Sengenes, C., Crampes, F., Lafontan, M. & Berlan, M. Functional and pharmacological characterization of the natriuretic peptidedependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther. 308, 984-992 (2004). (Pubitemid 38263974)
99. Li, P., Lin, J.E., Chervoneva, I., Schulz, S., Waldman, S.A. & Pitari, G.M. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 171, 1847-1858 (2007).
100. Li, P. et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133, 599-607 (2007). (Pubitemid 47187356)
101. Lin, J.E. et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 138, 241-254 (2010).
102. Lin, J.E. et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS ONE 7, e31686 (2012).
103. Valentino, M.A. et al. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J. Clin. Invest. 121, 3578-3588 (2011).
104. Ray, K. IBS: Linaclotide approved for constipation-predominant IBS. Nat. Rev. Gastroenterol. Hepatol. 9, 616 (2012).